« Targeting IL23p19 Using Risankizumab for the Management of Moderate-to-Severely Active Crohn’s Disease: The Next Frontier? », Can IBD Today, vol. 1, nᵒ S05, p. 2–7, mai 2023, doi: 10.58931/cibdt.2023.1S0510.